Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis
Nicolas A Nuñez,Boney Joseph,Mehak Pahwa,Rakesh Kumar,Manuel Gardea Resendez,Larry J Prokop,Marin Veldic,Ashok Seshadri,Joanna M Biernacka,Mark A Frye,Zhen Wang,Balwinder Singh,Nicolas A Nuñez,Boney Joseph,Mehak Pahwa,Rakesh Kumar,Manuel Gardea Resendez,Larry J Prokop,Marin Veldic,Ashok Seshadri,Joanna M Biernacka,Mark A Frye,Zhen Wang,Balwinder Singh
DOI: https://doi.org/10.1016/j.jad.2021.12.134
IF: 6.533
2022-04-01
Journal of Affective Disorders
Abstract:OBJECTIVE: To compare the efficacy and discontinuation of augmentation agents in adult patients with treatment-resistant depression (TRD). We conducted a systematic review and network meta-analyses (NMA) to combine direct and indirect comparisons of augmentation agents.METHODS: We included randomized controlled trials comparing one active drug with another or with placebo following a treatment course up to 24 weeks. Nineteen agents were included: stimulants, atypical antipsychotics, thyroid hormones, antidepressants, and mood stabilizers. Data for response/remission and all-cause discontinuation rates were analyzed. We estimated effect-size by relative risk using pairwise and NMA with random-effects model.RESULTS: A total of 65 studies (N = 12,415) with 19 augmentation agents were included in the NMA. Our findings from the NMA for response rates, compared to placebo, were significant for: liothyronine, nortriptyline, aripiprazole, brexpiprazole, quetiapine, lithium, modafinil, olanzapine (fluoxetine), cariprazine, and lisdexamfetamine. For remission rates, compared to placebo, were significant for: thyroid hormone(T4), aripiprazole, brexpiprazole, risperidone, quetiapine, and olanzapine (fluoxetine). Compared to placebo, ziprasidone, mirtazapine, and cariprazine had statistically significant higher discontinuation rates. Overall, 24% studies were rated as having low risk of bias (RoB), 63% had moderate RoB and 13% had high RoB.LIMITATIONS: Heterogeneity in TRD definitions, variable trial duration and methodological clinical design of older studies and small number of trials per comparisons.CONCLUSIONS: This NMA suggests a superiority of the regulatory approved adjunctive atypical antipsychotics, thyroid hormones, dopamine compounds (modafinil and lisdexamfetamine) and lithium. Acceptability was lower with ziprasidone, mirtazapine, and cariprazine. Further research and head-to-head studies should be considered to strengthen the best available options for TRD.
psychiatry,clinical neurology